Multidisciplinary

Top Medical News
Inferior vena cava filters safely reduce pulmonary embolism risk in VTE
2 hours ago
The use of inferior vena cava filters appears to effectively reduce the risk of pulmonary embolism (PE) and PE-related and all-cause deaths in patients with venous thromboembolism (VTE), reports a recent meta-analysis.
Inflammatory food may up dementia risk
Pearl Toh, 6 hours ago
Following a diet with high pro-inflammatory potential is associated with an increased risk of developing dementia, suggest data from the HELIAD* study.
Short-course, high-dose gatifloxacin gets a pass in multidrug-resistant TB with caveat
Jairia Dela Cruz, 6 hours ago
A short-term treatment regimen based on high-dose gatifloxacin appears to be effective against multidrug- or rifampicin-resistant tuberculosis (TB) but at the cost of increased severe adverse drug reactions, as shown in a study.
Botox injection achieves successful motor alignment in patients with strabismus
8 hours ago
Extraocular muscle injection of botulinum toxin type A (BTXA) results in a high rate of successful motor alignment, which is similar to that achieved following eye muscle surgery for nonparalytic, nonrestrictive horizontal strabismus, reports a recent study.
Air pollution in Hong Kong linked to gastrointestinal bleeding
Tristan Manalac, 11 hours ago
Despite significant progress in controlling air pollution, it remains an urgent public health problem, according to a recent European study, which found that more than 300,000 deaths in the region could be attributed to air pollution in 2019.
Breast cancer: Dense breasts may spell trouble for menopausal women
12 hours ago
An extremely dense breast prior to and after menopause may double the risk of breast cancer, according to a Korean cohort study.
AECOPD outcomes unaltered with short-course nonmacrolide therapy
14 hours ago
Short-course nonmacrolide therapy in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) appears to have no significant effect on outcomes including mortality, progression to ventilation, readmission rate, or prevalence of adverse drug events, a study has shown.
Special Reports
The Role of NOAC in Pandemic Era (TREND)
07 Dec 2021
At a Pfizer-sponsored Masterclass, four distinguished speakers shared their insights into the role of NOACs in the management of NVAF and VTE, with a focus on apixaban (Eliquis®, Pfizer). Furthermore, the speakers discussed a stepwise approach to guide treatment choice amid the COVID-19 pandemic.
Product Highlight - Locoa
01 Dec 2021
Esflurbiprofen 40 mg transdermal patch
Product Highlight - Rinvoq
01 Dec 2021
Upadacitinib 15 mg XR-FC tab
diabetes
01 Dec 2021
It has been estimated that diabetes – a chronic metabolic disorder resulting in hyperglycaemia – affects 422 million adults globally.1 In 2019, the disease caused 1.5 million deaths worldwide and the number of people with diabetes is expected to reach 642 million by 2040. 
Taking the big leapfrog to advance T2D care
01 Dec 2021
During the Guardians for Health Summit 2021 supported by Boehringer Ingelheim, several distinguished speakers shared their insights into the importance of type 2 diabetes (T2D) guideline adherence and patient empowerment, as well as the impact of clinical inertia on the burden of cardiorenal metabolic diseases.
Product Highlight - Evenity
01 Dec 2021
Romosozumab 105 mg/1.17 mL soln for inj
EMPEROR-Preserved: The first successful trial to improve outcomes in HFpEF
18 Nov 2021
Heart failure with preserved ejection fraction (HFpEF) represents a significant unmet medical need. The EMPEROR-Preserved trial aimed to assess the impact of empagliflozin on cardiovascular outcomes in patients with HFpEF. On 27 August 2021, during the hotline session of the 2021 ESC Virtual Congress, the main results of the EMPEROR-Preserved trial were presented by Professor Stefan Anker, principal investigator of the study, and heart failure specialist at Charité Berlin, Germany.
Conference Reports
Increased serum iron may hint at HCC risk in NAFLD patients
Roshini Claire Anthony, 07 Dec 2021

Increased serum iron or transferrin saturation levels in individuals with non-alcoholic fatty liver disease (NAFLD) may point to an increased risk of hepatocellular carcinoma (HCC), according to a study presented at The Liver Meeting Digital Experience™.

Switching to TAF helps improve virologic response in HBV patients in real world
Pearl Toh, 06 Dec 2021
Switching to tenofovir alafenamide (TAF) from nucleos(t)ide analogue therapies was associated with improved virologic response and liver function in patients with chronic hepatitis B virus (HBV) infection, even in those with decompensated HBV cirrhosis, according to real-world studies presented at AASLD 2021.
Interim findings boost therapeutic potential of lanifibranor for NASH
Audrey Abella, 06 Dec 2021
The pan-PPAR* agonist lanifibranor further advances into the NASH** treatment field, as more data from the phase IIb NATIVE*** study presented at AASLD 2021 unveil further histologic and therapeutic benefits for patients with NASH.
Empagliflozin beneficial and well tolerated in acute heart failure
Christina Lau, 06 Dec 2021

Empagliflozin provides a significant clinical benefit within 90 days and shows no safety concerns in patients hospitalized for acute heart failure (HF), according to results of the EMPULSE trial reported at the American Heart Association (AHA) Scientific Sessions 2021.

Canagliflozin improves HF symptoms, QoL regardless of diabetes status
Pearl Toh, 04 Dec 2021
The SGLT2i* canagliflozin significantly improves symptoms and quality of life (QoL) early on during treatment in people with heart failure (HF) due to either reduced or preserved ejection fraction (rEF or pEF), regardless of whether they have type 2 diabetes (T2D), according to the CHIEF-HF** study presented at AHA 2021.
Non-overweight NAFLD patients have poor liver transplant outcomes
Roshini Claire Anthony, 03 Dec 2021

Non-overweight patients with non-alcoholic fatty liver disease (NAFLD) have an elevated risk of all-cause mortality following liver transplant and are also more likely to be removed from the liver transplant waitlist compared with obese/overweight patients, according to a study presented at The Liver Meeting Digital Experience™.

Inclisiran sustains LDL-C reduction in high-risk patients with ASCVD
Elaine Soliven, 03 Dec 2021
Treatment with inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) levels in patients with, or at high risk of, atherosclerotic cardiovascular disease (ASCVD), regardless of glycaemic status, based on a pooled analysis of the ORION-10* and ORION-11** studies presented at AHA 2021.